Legend Capital Super Antibiotic Portfolio Company: Scarce Enterprise MicuRx Pharmaceuticals is Listed on the STAR Market Successfully
HONG KONG, Aug 09, 2022 - (ACN Newswire) - On August 5, 2022, Legend Capital portfolio company MicuRx Pharmaceuticals, a scarce enterprise in super antibiotic, was successfully listed on the STAR Market. MicuRx Pharmaceuticals issued 130,000,000 shares this time, accounting for 19.84% of the total share capital after the issuance. The total amount of funds raised is expected to be about RMB 960 million at the issue price of 8.16 yuan per share.
MicuRx Pharmaceuticals is an innovative drug company focusing on novel therapeutics for infectious diseases. With global independent intellectual property and competitiveness, MicuRx Pharmaceuticals is committed to the discovery, development, and commercialization of innovative drugs for unmet medical needs. The main products from MicuRx Pharmaceuticals include Contezolid, MRX-4, and MRX-8. Since the company's establishment, MicuRx Pharmaceuticals has adhered to the principle of "Better therapy through superior medicine", focusing on the increasingly severe problem of bacterial resistance worldwide. With the core competitiveness of solving clinical problems and differentiated innovation, MicuRx Pharmaceuticals aims to provide more effective and safer therapeutic options for patients suffering from the most common and severe drug-resistant bacterial infections. MicuRx Pharmaceuticals has an international core R&D team and has established R&D centers in China and the US. The company's R&D team has rich experience in international innovative drug development and management, and it has led or participated in developing a number of marketed anti-infective new drugs.
Legend Capital invested in MicuRx Pharmaceuticals in 2020 and has long supported the company's development. "Congratulations to MicuRx Pharmaceuticals. The successful listing represents the recognition of MicuRx Pharmaceuticals' innovative R&D in the field of multi-drug-resistant bacterial infection and its globally competitive innovative drug. Legend Capital and the MicuRx team have established a deep friendship, and Legend Capital is honored to participate in the MicuRx business led by Dr. Zhengyu YUAN, the founder of MicuRx Pharmaceuticals. Dr. YUAN is a very tenacious and spiritual entrepreneur who dares to take risks, filling the Chinese market gap in the scarce field of multi-drug-resistant bacterial infection. With the consolidation of the company's leading edge and position, Dr. YUAN has not only built an international team and an innovative global enterprise but also made positive contributions to the development of human health." Said Legend Capital.
Legend Capital has long paid close attention to investment in significant themes in the field of life sciences. In addition to MicuRx Pharmaceutical, Legend Capital has also made investments in plenty of other outstanding companies, many of which were listed on A-shares and H-shares, such as Pharmaron (300759.SZ) (03759.HK), Kingmed Diagnostics (603882.SH), Wuxi Apptec (603259.SH) (02359.HK), WuXi Biologics (02269.HK), Recbio (02179.HK), Innovent Biologics (01801.HK), Berry Genomics (000710.SZ), Harbour BioMed (02142.HK), New Horizon Health (06606.HK), and Chemclin Diagnostics (688468.SH).
About Legend Capital
Founded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies through solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital).
Source: Legend Capital Sectors: Healthcare & Pharm, PE, VC & Alternatives
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
 Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined with DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeostasis Jun 23, 2025 22:57 JST
|  Executive Appointments in Connection with the Establishment of NESIC Holdings Jun 23, 2025 19:22 JST
|  CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health Jun 20, 2025 19:06 JST
|  Sharp Launches A2 Size ePoster Color Electronic Paper Display Jun 19, 2025 12:08 JST
|  Fujitsu unveils AI-powered presentation technology, enabling automated multilingual and customizable presentations Jun 19, 2025 10:25 JST
|  ULVAC Continues Participation in "Lab-in-Fab" Project to Advance Piezoelectric MEMS Technology, Now Entering a New Phase Jun 19, 2025 09:30 JST
|  NEC and Chugai Pharmaceutical use AI to potentially enhance cancer treatment Jun 18, 2025 13:40 JST
|  Fujitsu awarded contract to design next-generation flagship supercomputer FugakuNEXT Jun 18, 2025 11:35 JST
|  Honda Celebrates 60th Anniversary of First F1 Victory with Special Events Program Jun 17, 2025 17:45 JST
|  MHI Receives Order to Supply 5 Models of Pumps, a Total of 34 Units, for Sizewell C Unit 1 and 2 in the UK from Trillium Flow Technologies Jun 17, 2025 17:10 JST
|  Honda Teams to Compete in 2025 FIM Endurance World Championship "Coca-Cola" Suzuka 8 Hours Endurance Road Race 46th Tournament Jun 16, 2025 16:37 JST
|  Fujitsu unveils Millimeter-Wave Monitoring System for enhanced safety and privacy in care facilities Jun 16, 2025 16:20 JST
|  Tat Hong Equipment Service Co., Ltd. Announces 2024/25 Annual Results Jun 13, 2025 22:49 JST
|  Yee Hop Holdings (1662.HK) Subsidiary APEL Launches Microfactory in Collaboration with HKPC Jun 13, 2025 21:38 JST
|  Jacobson Pharma Announces FY2025 Annual Results Jun 13, 2025 20:16 JST
|  TRENDE Announces Strategic Capital and Business Alliance with Tokyu Land Jun 13, 2025 13:00 JST
|  Supercomputer Fugaku retains first place worldwide in Graph500 rankings Jun 10, 2025 19:47 JST
|  International Consortium Rolls Out Major EV Battery Swapping Initiative in Tokyo Jun 06, 2025 16:42 JST
|  TANAKA PRECIOUS METAL TECHNOLOGIES Receives 2025 Technology Award from Catalyst Manufacturers Association, Japan, for Development and Practical Application of Electrode Catalysts for PEM Water Electrolysis Jun 06, 2025 11:00 JST
|  Fujitsu unveils Technology and Service Vision 2025: People-AI collaboration for a net positive future Jun 06, 2025 10:44 JST
|
More Latest Release >>
|